YOLFTbeta
Cue Biopharma

Cue Biopharma

CUE · NASDAQ · Healthcare / Biotechnology

16.12USD-1.38 (-7.89%)

Price History

Full chart

Market Stats

Previous Close17.50
Open17.69
Day Range14.30 – 17.69
52-Week Range4.97 – 45.50
Volume274.95K
Market Cap228.18M
P/E (TTM)0.00
Forward P/E0.00
EPS-29.24
Dividend Yield0.00%
Beta2.46
50-Day Avg29.33
200-Day Avg19.74

About

Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases. It also developed the Immuno-STAT platform, which targets disease-specific T cells in vivo without broad immune modulation. The company's lead autoimmune candidate is CUE-401, a bifunctional IL-2 and TGF-B program that is advancing towards Phase 1 development to regulate inflammation and drive Treg-mediated tolerance. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Shao-Lee Lin M.D., Ph.D.
  • Employees29
  • Headquarters40 Guest Street, Boston, MA, United States, 02135, USA
  • Websitehttps://www.cuebiopharma.com

Leadership

  • Ms. Lucinda WarrenPrincipal Accounting Officer & Chief Business Officer · b. 1969
  • Mr. Colin G. Sandercock J.D., MSESenior Vice President of Intellectual Property · b. 1957
  • Dr. Shao-Lee Lin M.D., Ph.D.President, CEO & Director · b. 1967
  • Dr. Ronald D. Seidel III, Ph.D.Co-Founder · b. 1976
  • Dr. Rodolfo Jose Chaparro Ph.D.Co-Founder · b. 1973
  • Dr. Steven C. Almo Ph.D.Co-Founder and Chairman of Scientific & Clinical Advisory Board · b. 1961
  • Mr. James M. AhlersChief Financial Officer · b. 1964
  • Ms. Agnes LeeChief Officer of Public & Investor Relations
  • Ms. Sumita Ray J.D.Chief Legal & Compliance Officer and Corporate Secretary · b. 1974
  • Dr. Daniel G. Baker M.D., Ph.D.Interim Chief Development Officer · b. 1950

Financials

Income Statement

Currency: USD2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue0001.14M3.46M3.15M14.94M1.25M5.49M9.29M27.47M
Growth (%)----+202.64%-8.78%+373.68%-91.67%+340.96%+69.16%+195.75%
Cost of Revenue44.81K202.09K419.57K28.54M27.49M33.55M-1.78M1.81M38.10M2.35M3.48M
Gross Profit-44.81K-202.09K-419.57K-27.40M3.46M-30.39M14.94M1.25M-32.61M9.29M27.47M
Gross Margin----2398.16%100.00%-963.48%100.00%100.00%-593.93%100.00%100.00%
Operating Expense1.88M7.46M22.81M11.30M40.23M14.65M58.65M54.47M19.54M50.79M53.99M
Operating Income-1.93M-7.66M-23.23M-38.70M-36.77M-45.04M-43.71M-53.23M-52.15M-41.50M-26.52M
Operating Margin----3386.71%-1063.30%-1427.96%-292.56%-4275.10%-949.89%-446.86%-96.56%
EBITDA-1.88M-7.46M-22.81M-37.94M-31.60M-43.99M-45.49M-50.49M-46.05M-37.53M-22.27M
EBITDA Margin----3320.19%-913.92%-1394.44%-304.46%-4055.50%-838.83%-404.09%-81.06%
Net Income-1.93M-7.66M-23.23M-38.98M-36.70M-44.78M-44.16M-53.01M-50.73M-40.67M-26.60M
Net Income Margin----3411.53%-1061.25%-1419.79%-295.56%-4257.83%-924.10%-437.97%-96.85%
R&D1.50M5.69M18.90M28.54M27.49M33.55M41.35M38.58M40.80M36.30M37.74M
R&D as % of Total Revenue---2498.16%794.88%1063.48%276.73%3098.63%743.21%390.82%137.42%
Interest Expense00005.65M463.91K1.73M713.82K1.25M796.00K357.00K
Interest Expense % of Total Revenue---0.00%163.35%14.71%11.59%57.33%22.68%8.57%1.30%

Balance Sheet

Currency: USD2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets7.31M16.28M66.95M45.36M71.61M99.53M83.40M91.28M61.53M32.19M42.21M
Total Liabilities376.30K1.10M5.35M11.39M17.02M20.62M17.91M25.60M24.45M14.69M15.78M
Total Equity6.94M15.17M61.61M33.97M54.58M78.91M65.49M65.68M37.09M17.50M26.43M
Cash6.41M14.93M63.53M20.80M44.29M74.87M64.37M51.61M48.51M22.46M27.14M
Total Debt--2.50M-5.80M7.15M12.02M19.32M14.70M8.88M4.20M
Net Debt-6.41M-14.93M-61.03M-20.80M-38.49M-67.72M-52.35M-32.30M-33.82M-13.58M-22.94M

Cash Flow

Currency: USD2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-1.66M-5.97M-12.19M-26.41M-30.80M-32.49M-38.84M-41.81M-39.96M-36.33M-21.69M
Investing Cash Flow-804.29K-516.01K-1.20M-20.35M3.45M4.46M9.11M-24.61M25.00M32.00K75.00K
Financing Cash Flow8.87M15.01M62.00M4.18M50.79M58.61M19.23M53.66M11.86M10.24M26.29M
Capital Expenditure754.29K515.98K1.20M1.85M46.35K595.26K913.04K171.00K066.00K177.00K
Free Cash Flow-2.41M-6.48M-13.40M-28.27M-30.84M-33.09M-39.75M-41.98M-39.96M-36.40M-21.86M
Dividends Paid-------199.87K---
FCF to OCF145.51%108.65%109.88%107.02%100.15%101.83%102.35%100.41%100.00%100.18%100.82%
Dividend Paid to FCF--------0.48%---

Earnings

Report DateMay 4, 2017Nov 2, 2017Mar 29, 2018May 14, 2018Aug 13, 2018Nov 13, 2018Mar 14, 2019May 8, 2019Aug 8, 2019Nov 7, 2019Mar 12, 2020May 7, 2020Aug 10, 2020Nov 9, 2020Mar 9, 2021May 10, 2021Aug 9, 2021Nov 9, 2021Mar 16, 2022May 10, 2022Aug 4, 2022Nov 14, 2022Mar 21, 2023May 9, 2023Aug 8, 2023Nov 3, 2023Mar 28, 2024May 9, 2024Aug 14, 2024Nov 14, 2024Mar 26, 2025May 12, 2025Aug 12, 2025Nov 12, 2025Mar 24, 2026May 14, 2026Aug 14, 2026Nov 11, 2026
EPS Estimate0.000.000.00---11.40-0.40-12.00-16.80-13.20-0.45-11.18-12.75-11.40-0.35-10.65-12.00-11.10-0.38-12.60-12.00-11.40-0.31-8.70-9.15-10.28-0.28-8.78-8.40-5.70-0.14-4.60-3.90-2.55-0.09-3.30-1.69-4.04
EPS Actual-0.31-0.47-0.63-0.37-0.36-18.60-0.58-16.20-13.80-9.30-0.36-14.40-11.40-10.20-0.36-12.30-9.90-12.30-0.25-13.20-11.10-9.30-0.38-8.70-8.70-7.20-0.29-7.50-6.00-5.13-0.13-5.10-2.70-2.100.01-1.08-13.81-
Surprise------63.16%-45.00%-35.00%17.86%29.55%20.00%-28.80%10.59%10.53%-2.86%-15.49%17.50%-10.81%34.21%-4.76%7.50%18.42%-22.58%0.00%4.92%29.96%-3.57%14.58%28.57%10.00%11.72%-10.87%30.77%17.65%111.11%67.27%-717.16%-
Timing--After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hours-

Key Statistics & Ratios

Market Cap228.18M
Enterprise Value214.88M
Trailing P/E0.00
Forward P/E0.00
Price / Sales6.06
Price / Book99.22
EPS-29.24
Book Value0.442
Revenue (TTM)37.66M
Gross Profit (TTM)-37.34M
EBITDA-97.28M
Profit Margin0.00%
Operating Margin-1113.31%
Return on Equity-1603.48%
Return on Assets-172.66%
Shares Outstanding7.26M
Shares Float6.85M
Beta2.46
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 4 analystsTarget 88.00
  • Strong Buy
    2
  • Buy
    2

Ownership Breakdown

Institutions
22.82%
Insiders
9.44%
Retail / Other
67.74%

Top Institutional Holders

  • Bleichroeder LP
    6.82M3.13%
  • Polygon Management Ltd
    93.82K1.29%
  • Vanguard Capital Management, LLC
    2.46M1.13%
  • Lion Point Capital, LP
    52.93K0.73%
  • Squadron Capital Management LLC
    50.00K0.69%
  • Diadema Partners LP
    48.37K0.67%
  • Geode Capital Management, LLC
    1.06M0.49%
  • Vanguard Fiduciary Trust Co
    543.59K0.25%
  • BlackRock Inc
    449.16K0.21%
  • Stifel Financial Corp
    246.56K0.11%
  • Renaissance Technologies Corp
    213.83K0.10%
  • Bank of America Corp
    207.71K0.10%
  • State Street Corp
    179.35K0.08%
  • Northern Trust Corp
    94.61K0.04%
  • UBS Group AG
    88.35K0.04%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    111.87K1.54%
  • Fidelity Extended Market Index
    19.84K0.27%
  • iShares Micro-Cap ETF
    11.06K0.15%
  • Fidelity Total Market Index
    7.25K0.10%
  • Fidelity Series Total Market Index
    5.95K0.08%

Stock Splits

  • Apr 24, 20261:30